ESSA Pharma (EPIX) shares plunged 70% in recent Friday premarket activity, a day after saying it planned to terminate a phase 2 clinical study evaluating the combination of masofaniten and enzalutamide in patients with metastatic castration-resistant prostate cancer compared with enzalutamide.
Lexicon Pharmaceuticals (LXRX) stock tumbled 37%, after saying late Thursday that the US Food and Drug Administration's Endocrinologic and Metabolic Drugs Advisory Committee said the company's Zynquista inhibitor's benefits do not "outweigh" the risks in adults having type 1 diabetes and chronic kidney disease.
DigitalBridge Group (DBRG) shares were down 6% after it reported lower Q3 distributable earnings and total revenue compared with a year earlier.
Telephone and Data Systems (TDS) stock slipped nearly 6% after it reported a wider Q3 net loss and lower revenue compared with last year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.